Skip to Content

9 Results Found

  • Review
  • Open Access
19 Citations
11,548 Views
14 Pages

20 October 2024

Amyotrophic lateral sclerosis (ALS) is a refractory neurodegenerative disease characterized by the degeneration and loss of motor neurons, typically resulting in death within five years of onset. There have been few effective treatments, making the d...

(This article belongs to the Section Human Genomics and Genetic Diseases)
  • Article
  • Open Access
1,451 Views
20 Pages

Longitudinal CSF and Serum Biomarker Dynamics in Tofersen-Treated SOD1-ALS: A Real-World Multicentre Cohort Study

  • Andrea Giordano,
  • Jessica Mandrioli,
  • Federica Cerri,
  • Christian Lunetta and ,
  • Hamidreza Saebfar,
  • Marcella Catania,
  • Claudia Battipaglia,
  • Laura Leone,
  • Francesca Trojsi and
  • Nilo Riva
  • + 18 authors+ 13 authors

Tofersen is a gene-targeted therapy for superoxide dismutase 1 (SOD1)-associated amyotrophic lateral sclerosis (ALS), but neurofilament light chain (NfL) may not fully capture the biological response to treatment. We performed a multicentre retrospec...

(This article belongs to the Special Issue Molecular and Cellular Mechanisms in Amyotrophic Lateral Sclerosis)
  • Abstract
  • Open Access
1,212 Views
2 Pages

Tofersen: The Use of Antisense Oligonucleotide as a Therapeutic Approach to SOD1-Associated Amyotrophic Lateral Sclerosis—A Literature Review

  • Isaac D. S. V. Prado,
  • Ana C. F. Leite,
  • Lavínia H. A. Torres,
  • Luigi Gallo and ,
  • Mateus G. C. Soares,
  • Samuel C. Da Silva and
  • Carlos N. Aucélio
  • + 2 authors+ 0 author

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that affects motor neurons, causing weakness and atrophy [...]

(This article belongs to the Proceedings of The 6th International Congress on Health Innovation—INOVATEC 2025)
  • Review
  • Open Access
45 Citations
12,509 Views
25 Pages

Antisense oligonucleotides (ASOs) are short oligodeoxynucleotides designed to bind to specific regions of target mRNA. ASOs can modulate pre-mRNA splicing, increase levels of functional proteins, and decrease levels of toxic proteins. ASOs are being...

(This article belongs to the Special Issue Neurodegenerative Disease: From Molecular Basis to Therapy, 2nd Edition)
  • Review
  • Open Access
94 Citations
14,029 Views
13 Pages

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest

  • Danah Al Shaer,
  • Othman Al Musaimi,
  • Fernando Albericio and
  • Beatriz G. de la Torre

13 February 2024

A total of nine TIDES (pepTIDES and oligonucleoTIDES) were approved by the FDA during 2023. The four approved oligonucleotides are indicated for various types of disorders, including amyotrophic lateral sclerosis, geographic atrophy, primary hyperoxa...

(This article belongs to the Section Biopharmaceuticals)
  • Review
  • Open Access
5 Citations
2,865 Views
28 Pages

Amyotrophic Lateral Sclerosis (ALS) Genetics and Microbiota: A Comprehensive Review

  • Mostafa Ahmed Kurdi,
  • Hidayah Alotaibi,
  • Asayel Tawfiq Alkhuraymi,
  • Layyan Nassar Aldahery and ,
  • Ali Fouad Alhawaj and
  • Hamzah Jehad Aldali
  • + 1 author+ 0 author

19 February 2026

Amyotrophic Lateral Sclerosis (ALS) is a severe, progressive neurodegenerative disorder characterized by the loss of upper and lower motor neurons, affecting 0.5 to 2.6 per 100,000 people, with a median survival of 2 to 5 years. It is increasingly se...

(This article belongs to the Special Issue Understanding and Treating Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases)
  • Review
  • Open Access
492 Views
22 Pages

The Role of SOD1 and Oxidative Stress in Amyotrophic Lateral Sclerosis: An Overview

  • Carlos Alberto Gómez-Pérez,
  • Miguel Ángel Ramírez-García and
  • Petra Yescas-Gómez

13 October 2026

Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disorder that selectively affects motor neurons. The median survival time after diagnosis is 2 to 5 years. Oxidative stress (OS), driven mainly by reactive oxygen species...

(This article belongs to the Special Issue Oxidative and Redox Signalling in Neurological Diseases)
  • Review
  • Open Access
1 Citations
802 Views
17 Pages

5 September 2026

Amyotrophic lateral sclerosis (ALS) usually enters diagnostic pathways after motor symptoms emerge, by which time neural injury has been ongoing. Long-term hereditary ALS cohorts show that some pathogenic-variant carriers may show elevated neurofilam...

(This article belongs to the Special Issue Diagnostic, Predictive and Prognostic Biomarkers for Neurodegenerative Diseases)
  • Review
  • Open Access
38 Citations
16,323 Views
36 Pages

14 April 2025

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the progressive degeneration of upper and lower motor neurons, leading to muscle atrophy, paralysis, and respiratory failure. This comprehensive review s...

(This article belongs to the Section Physiology and Pathology)